Amphastar Pharmaceuticals Inc (AMPH)
NASDAQ:AMPH
Want to see AMPH full AI Analyst Report?
Total Valuation
Amphastar Pharmaceuticals has a market cap or net worth of $758.40M. The enterprise value is $1.31B.
Market Cap$758.40M
Enterprise Value$1.31B
Share Statistics
Amphastar Pharmaceuticals has 44,092,920 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding44,092,920
Owned by Insiders27.14%
Owned by Institutions15.75%
Financial Efficiency
Amphastar Pharmaceuticals’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 7.52%.
Return on Equity (ROE)0.12
Return on Assets (ROA)0.06
Return on Invested Capital (ROIC)7.52%
Return on Capital Employed (ROCE)0.10
Revenue Per Employee354.97K
Profits Per Employee0.00
Employee Count2,028
Asset Turnover0.44
Inventory Turnover2.06
Valuation Ratios
The current PE Ratio of Amphastar Pharmaceuticals is 34.6. Amphastar Pharmaceuticals’s PEG ratio is -0.35.
PE Ratio34.6
PS Ratio1.74
PB Ratio1.59
Price to Fair Value1.59
Price to FCF10.33
Price to Operating Cash Flow4.78
PEG Ratio-0.35
Income Statement
In the last 12 months, Amphastar Pharmaceuticals had revenue of 719.89M and earned 98.09M in profits. Earnings per share was 2.10.
Revenue719.89M
Gross Profit356.06M
Operating Income140.40M
Pretax Income123.62M
Net Income98.09M
EBITDA149.10M
Earnings Per Share (EPS)2.10
Cash Flow
In the last 12 months, operating cash flow was 168.88M and capital expenditures -33.69M, giving a free cash flow of 135.19M billion.
Operating Cash Flow168.88M
Free Cash Flow135.19M
Free Cash Flow per Share3.07
Dividends & Yields
Amphastar Pharmaceuticals pays an annual dividend of $0.3, resulting in a dividend yield of ―
Dividend Per Share$0.3
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.86
52-Week Price Change-26.24%
50-Day Moving Average20.24
200-Day Moving Average24.96
Relative Strength Index (RSI)37.78
Average Volume (3m)583.23K
Important Dates
Amphastar Pharmaceuticals upcoming earnings date is Aug 10, 2026, After Close (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 10, 2026
Ex-Dividend Date―
Financial Position
Amphastar Pharmaceuticals as a current ratio of 4.02, with Debt / Equity ratio of 88.75%
Current Ratio4.02
Quick Ratio2.90
Debt to Market Cap0.49
Net Debt to EBITDA3.26
Interest Coverage Ratio5.51
Taxes
In the past 12 months, Amphastar Pharmaceuticals has paid 25.53M in taxes.
Income Tax25.53M
Effective Tax Rate0.21
Enterprise Valuation
Amphastar Pharmaceuticals EV to EBITDA ratio is 11.65, with an EV/FCF ratio of 14.33.
EV to Sales2.41
EV to EBITDA11.65
EV to Free Cash Flow14.33
EV to Operating Cash Flow11.13
Balance Sheet
Amphastar Pharmaceuticals has $294.39M in cash and marketable securities with $686.38M in debt, giving a net cash position of -$391.99M billion.
Cash & Marketable Securities$294.39M
Total Debt$686.38M
Net Cash-$391.99M
Net Cash Per Share-$8.89
Tangible Book Value Per Share$4.77
Margins
Gross margin is 47.34%, with operating margin of 19.50%, and net profit margin of 13.63%.
Gross Margin47.34%
Operating Margin19.50%
Pretax Margin17.17%
Net Profit Margin13.63%
EBITDA Margin20.71%
EBIT Margin20.71%
Analyst Forecast
The average price target for Amphastar Pharmaceuticals is $22.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$22.00
Price Target Upside-3.85% Downside
Analyst ConsensusHold
Analyst Count6
Revenue Growth Forecast-1.39%
EPS Growth Forecast-41.70%